scholarly journals Hematopoietic Cell Transplantation Co-Morbidity Index (HCT-CI) to Predict Non Relapse Mortality (NRM) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

2012 ◽  
Vol 18 (2) ◽  
pp. S330
Author(s):  
M.P. Colella ◽  
E.C.M. Miranda ◽  
F.J.P. Aranha ◽  
V.C.A. Fernandes-Junior ◽  
S.M. Medina ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Hematopoietic Stem ◽  
Co Morbidity ◽  
Morbidity Index

scholarly journals COVID-19 INFECTION IN A CANDIDATE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT

JBMTCT ◽  
2020 ◽  
Vol 2 (1) ◽  
pp. 33-36
Author(s):  
Mateus Lavor Lira ◽  
Yara Ceres E Silva Ferreira Lima ◽  
Isaias Lima De Figueiredo Júnior ◽  
Osvaldo Pimentel Oliveira Neto ◽  
Isabella Araujo Duarte ◽  
...  
Keyword(s):  
Stem Cell ◽  
Case Report ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Hematopoietic Stem ◽  
Autologous Hematopoietic Cell Transplantation

The pandemic for the new coronavirus SARS-CoV-2 has been the causeof enormous challenges for the entire health system, especially in programs who dealwith Hematopoietic Stem Cell Transplantation (TCTH), since sequelae related to COVID-19 can be a hindrance to a possible HSCT. In case report, VBF, 61 years old, diagnosis of classic lymphocyte-rich Hodgkin'slymphoma in 2018 with initial treatment with ABVD, due to the return of the disease, an ICE regimen was started, but with disease progression after 5 cycles. Then, an IGEV scheme was started with a schedule of autologous hematopoietic cell transplantation, which took place in the third cycle in May / 2020. However, at the end of May / 2020, he was admitted to the emergency department with confirmation of SARS-Cov-2 infection by means of PCR of the nasal and oropharyngeal swab. He evolved during hospitalization with hypoxemic respiratory failure, mechanical ventilation and signs of secondary pulmonary infection, using multiple antimicrobial regimens, showing improvement and finally being extubated. However, he presented important pulmonary sequelae, with chest CT showing extensive cavitation in the left upper lobe and reticular opacities, with distortion of the pulmonary architecture. He was reassessed as to the possibility of autologous hematopoietic cell transplantation, but this was contraindicated due to pulmonary sequelae. In the case reported, the patient complied with the formal indication for HSCT, which would be refractoriness or relapse in a second remission in patients up to 70 years old with sensitivity to rescue schemes. However, due to pulmonary sequelae acquired after COVID-19, HSCT was contraindicated. This case leads us to the conclusion that the pandemic by the SARS-CoV-2 coronavirus can directly affect HSCT services and that in addition to preventing infection in this group of patients, they should be reevaluated after the recovery of COVID-19 for evaluation of structural and functional respiratory sequelae.

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Patients (pts) Older Than 50 Years: a Retrospective Single Center Study

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3309-3309
Author(s):  
Marie Robin ◽  
Raphael Porcher ◽  
Lionel Ades ◽  
Emmanuel Raffoux ◽  
Régis Peffault de Latour ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Conditioning Regimen ◽  
Refractory Anemia ◽  
Unrelated Donor ◽  
Hematopoietic Stem ◽  
Co Morbidity

Abstract Background: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment in MDS, and also in many cases of AML, 2 diseases where median age is higher than 50 years. Aim: Analyse the outcome of patients older than 50 years who received an allogeneic hematopoietic stem cell transplantation (HSCT) for MDS or AML, in Saint-Louis Hospital from January 1997 to December 2007. Method: 48 patients (pts) aged from 50 to 68 years (median: 56) received an HSCT for MDS (N=28) or AML (N=20) during this period. AML pts had intermediate (n=15) or high risk cytogenetics (n=3). 8 pts had failure to initial induction chemotherapy. FAB classification for MDS was: RAEB (n=8), RAEBt (n=6), secondary AML (n=2) or refractory anemia (n=2). Maximal IPSS score was high, intermediate-2 and intermediate-1 in 11, 14 and 4 pts. Ten pts with MDS received an “AML-like” chemotherapy and 5 received demethylating agents before transplant. 18 of the AML pts were in complete remission (CR) at time of transplant (CR1, n=15; CR2, n=3) and 2 were in relapse at time of HSCT. 10, 9 and 9 patients with MDS had < 5%, 5–10% and > 10% blasts in bone marrow at time of HSCT. Results: 19 patients with AML (95%) and 16 patients with MDS (57%) received a HSCT from an HLA-identical sibling donor. Other pts received a matched unrelated donor. Thirty-two pts, including 9/20 and 23/28 had at least one co-morbidity according to Sorror score. The conditioning regimen was myeloablative (MAC) in 14 pts (29%). Reduced intensity (RIC) was fludarabine based in 34 pts, associated with either 2 Gy TBI (n=25) or chemotherapy (n=9). All pts engrafted. 35 pts had acute graft-versus-host disease (GVHD): grade I in 11, grade II in 18 and grade III in 6. GVHD incidence did not differ between pts who received a MAC or a RIC regimen. Two-year overall survival (OS) was 41% (95% CI: 26–57). OS and relapse-free-survival (RFS) were similar after MAC or RIC regimen (OS: 29% vs 35% and RFS: 29% vs 30%). Short-term non-relapse mortality (NRM) was lower in patients who received a RIC as compared to patients who received a MAC regimen but was similar at long-term (6-month NRM = 21% vs 9% and 12-month NRM = 21 vs 19 %). Patients with AML or MDS had similar OS and RFS (OS: 42 vs 41%; RFS: 37 vs 26% at 2 years for AML and MDS, respectively). NRM was not significantly higher in pts with MDS (26 vs 10% at one year) whereas relapse rate was not significantly higher in pts with AML (13 vs 6%). Conclusion: HSCT for AML or MDS after 50 years is a curative option for pts with related or unrelated HLA-identical donor regardless kind of conditioning regimen and co-morbidity at time of transplantation.

scholarly journals APPENDICEAL DISEASE IN HEMATOPOIETIC CELL TRANSPLANTATION

2021 ◽  
Author(s):  
Zachary Wright ◽  
Francis Essien ◽  
John Renshaw ◽  
Michael Wiggins ◽  
Alexander Brown ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Medical Therapy ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Stem ◽  
Post Transplant ◽  
Transplant Patients

Appendiceal diseases are relatively rare reported complications during hematopoietic stem cell transplantation with no guidance on management. Pre- and post-transplant patients should receive a trial of medical therapy with appendectomy after recovery but prior to transplant in the former and plan for appendectomy after completion of immunosuppression in the latter.

Sign in / Sign up

Export Citation Format

Share Document